2023
Where Are the Children? A Thematic Analysis of State, Territory, and Tribal Organization Comprehensive Cancer Control Plans
Leraas H, Beckhorn C, Washabaugh C, Thamby J, Greenup R, Haines K, Allen L, Tracy E. Where Are the Children? A Thematic Analysis of State, Territory, and Tribal Organization Comprehensive Cancer Control Plans. Journal Of Pediatric Surgery 2023, 59: 129-133. PMID: 37858391, DOI: 10.1016/j.jpedsurg.2023.09.022.Peer-Reviewed Original ResearchConceptsComprehensive Cancer Control ProgramPediatric cancer careCancer careChildhood cancerEarly detectionPediatric cancer survivorshipComprehensive cancer control plansDistrict of ColumbiaCancer control programsCancer control plansAdult cancer riskU.S. territoriesTreatment disparitiesPediatric oncologyRisk factorsCancer preventionLevel IVCancer survivorshipCancer riskPediatric cancerChildhood exposureCancerCancer treatmentCareTribal organizationsRelative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US
Kc M, Fan J, Hyslop T, Hassan S, Cecchini M, Wang S, Silber A, Leapman M, Leeds I, Wheeler S, Spees L, Gross C, Lustberg M, Greenup R, Justice A, Oeffinger K, Dinan M. Relative Burden of Cancer and Noncancer Mortality Among Long-Term Survivors of Breast, Prostate, and Colorectal Cancer in the US. JAMA Network Open 2023, 6: e2323115. PMID: 37436746, PMCID: PMC10339147, DOI: 10.1001/jamanetworkopen.2023.23115.Peer-Reviewed Original ResearchConceptsLong-term survivorsCancer-specific mortalityColorectal cancerCancer cohortReceptor statusInitial diagnosisGleason scoreProstate cancerBreast cancerLong-term adult survivorsMedian cancer-specific survivalEnd Results cancer registryProstate-specific antigen levelRectal cancer cohortCancer-specific survivalStage III diseaseYear of diagnosisProgesterone receptor statusEstrogen receptor statusProportion of deathsSurvival time ratioEarly-stage cancerNononcologic outcomesIndex cancerLocalized diseaseMultidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer
Wheeler S, Spencer J, Manning M, Samuel C, Reeder‐Hayes K, Greenup R, Spees L, Rosenstein D. Multidimensional financial hardship among uninsured and insured young adult patients with metastatic breast cancer. Cancer Medicine 2023, 12: 11930-11940. PMID: 37148550, PMCID: PMC10242847, DOI: 10.1002/cam4.5885.Peer-Reviewed Original Research
2022
Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021
Chehayeb R, Hood A, Wang X, Miksad R, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment Sequencing Patterns and Associated Direct Medical Costs of Metastatic Breast Cancer Care in the United States, 2011 to 2021. JAMA Network Open 2022, 5: e2244204. PMID: 36445704, PMCID: PMC9709649, DOI: 10.1001/jamanetworkopen.2022.44204.Peer-Reviewed Original ResearchConceptsMetastatic breast cancerErbB2-positive metastatic breast cancerHR-positive metastatic breast cancerLines of therapyMBC subtypesDrug costsBreast cancerMedical costsHuman epidermal growth factor receptor 2 receptor statusMBC treatmentERBB2-negative metastatic breast cancerAssociated direct medical costsEarly-stage breast cancerHormone receptorsFlatiron Health databaseMetastatic recurrence ratesDifferent drug regimensBreast cancer careData of patientsDirect medical costsNovel adjuvant therapySupportive care drugsOutcomes of interestCost-effectiveness analysisAdjuvant therapy
2018
The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT)
Fayanju O, Ren Y, Thomas S, Greenup R, Plichta J, Rosenberger L, Tamirisa N, Force J, Boughey J, Hyslop T, Hwang E. The Clinical Significance of Breast-only and Node-only Pathologic Complete Response (pCR) After Neoadjuvant Chemotherapy (NACT). Annals Of Surgery 2018, 268: 591-601. PMID: 30048319, PMCID: PMC6496955, DOI: 10.1097/sla.0000000000002953.Peer-Reviewed Original ResearchConceptsPathologic complete responseImproved overall survivalNeoadjuvant chemotherapyOverall survivalComplete responseBreast cancerHuman epidermal growth factor receptor 2 (HER2) statusEpidermal growth factor receptor 2 statusCox proportional hazards modelHormone receptorsNode-positive patientsTriple-negative diseaseKaplan-Meier curvesBreast cancer patientsMultivariate logistic regressionProportional hazards modelAnatomic extentCancer patientsReceptor subtypesClinical significanceHazards modelTumor subtypesPatientsBreastLogistic regressionThe Effect of Hospital Volume on Breast Cancer Mortality
Greenup R, Obeng-Gyasi S, Thomas S, Houck K, Lane W, Blitzblau R, Hyslop T, Hwang E. The Effect of Hospital Volume on Breast Cancer Mortality. Annals Of Surgery 2018, 267: 375-381. PMID: 27893532, PMCID: PMC5994238, DOI: 10.1097/sla.0000000000002095.Peer-Reviewed Original ResearchConceptsHigh-volume centersNational Cancer Data BaseHospital volumeVolume centersBreast cancerHazard ratioImproved survivalStage 0Case volumeMultivariable Cox proportional hazards modelsMultidisciplinary breast cancer treatmentMultivariable Cox proportional hazardsSurgeons National Cancer Data BaseCox proportional hazards modelAnnual hospital volumeLess common cancersUnilateral breast cancerBreast cancer mortalityBreast cancer patientsCubic spline analysisLog-rank testBreast cancer treatmentCox proportional hazardsProportional hazards modelHigher case volumeOncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study
Jakub J, Peled A, Gray R, Greenup R, Kiluk J, Sacchini V, McLaughlin S, Tchou J, Vierkant R, Degnim A, Willey S. Oncologic Safety of Prophylactic Nipple-Sparing Mastectomy in a Population With BRCA Mutations: A Multi-institutional Study. JAMA Surgery 2018, 153: 123-129. PMID: 28903167, PMCID: PMC5838709, DOI: 10.1001/jamasurg.2017.3422.Peer-Reviewed Original ResearchConceptsProphylactic nipple-sparing mastectomyNipple-sparing mastectomyRisk-reducing mastectomyPrimary breast cancerBRCA mutationsBreast cancerOncologic safetyContralateral risk-reducing mastectomyNew primary breast cancerOccult primary breast cancerCancer risk-reducing strategiesIpsilateral breast cancerNew breast cancersBreast cancer eventsCohort of patientsNipple-sparing mastectomiesPrimary outcome measureBRCA1/2 mutation carriersFree nipple graftSuperior cosmetic outcomesEvidence-based dataHealth care professionalsMulti-institutional studyNipple-areolar complexProphylactic side
2017
Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer.
Spring L, Greenup R, Niemierko A, Schapira L, Haddad S, Jimenez R, Coopey S, Taghian A, Hughes K, Isakoff S, Ellisen L, Smith B, Specht M, Moy B, Bardia A. Pathologic Complete Response After Neoadjuvant Chemotherapy and Long-Term Outcomes Among Young Women With Breast Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 1216-1223. PMID: 28982747, DOI: 10.6004/jnccn.2017.0158.Peer-Reviewed Original ResearchMeSH KeywordsAdultAge FactorsAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBreast NeoplasmsFemaleFollow-Up StudiesHumansMutationNeoadjuvant TherapyNeoplasm GradingNeoplasm StagingRecurrenceRegistriesRetrospective StudiesSurvival AnalysisTreatment OutcomeTriple Negative Breast NeoplasmsYoung AdultConceptsPathologic complete responseDisease-free survivalBaseline clinical stageNeoadjuvant chemotherapyOverall survivalBreast cancerYoung womenComplete responseClinical stageResidual diseaseInvasive breast cancerLong-term outcomesAggressive tumor biologyMassachusetts General HospitalDFS ratesNeoadjuvant therapyOS ratesSurvival outcomesSurrogate markerGeneral HospitalBest therapyHigh riskTrial designRapid triagePatientsAssociation Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis
Shammas R, Cho E, Glener A, Poveromo L, Mundy L, Greenup R, Blackwell K, Hollenbeck S. Association Between Targeted HER-2 Therapy and Breast Reconstruction Outcomes: A Propensity Score-Matched Analysis. Journal Of The American College Of Surgeons 2017, 225: 731-739.e1. PMID: 28985927, DOI: 10.1016/j.jamcollsurg.2017.08.023.Peer-Reviewed Original ResearchConceptsPostoperative wound breakdownBreast reconstructionReconstructive complicationsWound breakdownReconstructive operationsPropensity score-matched pairsMastectomy skin flap necrosisDuke University Medical CenterAdministration of trastuzumabPrimary study outcomeSkin flap necrosisLarger tumor sizePost-mastectomy reconstructionBreast reconstruction outcomesOccurrence of hematomaUniversity Medical CenterPertuzumab therapyChemotherapy regimenNeoadjuvant chemotherapyOperative interventionFlap thrombosisTrastuzumab therapySurgical outcomesTumor sizeFlap necrosisCost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer
Gamble C, Havrilesky L, Myers E, Chino J, Hollenbeck S, Plichta J, Kelly Marcom P, Shelley Hwang E, Kauff N, Greenup R. Cost Effectiveness of Risk-Reducing Mastectomy versus Surveillance in BRCA Mutation Carriers with a History of Ovarian Cancer. Annals Of Surgical Oncology 2017, 24: 3116-3123. PMID: 28699130, PMCID: PMC5990891, DOI: 10.1245/s10434-017-5995-z.Peer-Reviewed Original ResearchConceptsRisk-reducing mastectomyOvarian cancer diagnosisIncremental cost-effectiveness ratioBRCA mutation carriersMonths of lifeMutation carriersMagnetic resonance imagingCancer diagnosisSurvival benefitOvarian cancerMutation statusMost BRCA1/2 mutation carriersThird-party payer perspectiveGreater survival benefitBreast cancer riskBRCA mutation statusBRCA1/2 mutation carriersBRCA2 mutation carriersBRCA2 mutation statusBRCA1 mutation carriersBreast cancer screeningMonte Carlo probabilistic sensitivity analysisCost-effectiveness ratioYears of lifeProbabilistic sensitivity analysesBreast Cancer after Augmentation
Cho E, Shammas R, Phillips B, Greenup R, Hwang E, Hollenbeck S. Breast Cancer after Augmentation. Plastic & Reconstructive Surgery 2017, 139: 1240e-1249e. PMID: 28538550, DOI: 10.1097/prs.0000000000003342.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBreast ImplantationBreast ImplantsBreast NeoplasmsCohort StudiesFemaleFollow-Up StudiesHumansIncidenceLogistic ModelsMammaplastyMastectomyMiddle AgedMultivariate AnalysisPostoperative ComplicationsReference ValuesRetrospective StudiesRisk AssessmentStatistics, NonparametricSurgical FlapsTime FactorsTreatment OutcomeUnited StatesConceptsPrior augmentationBreast cancer stageBreast cancerSubglandular augmentationCancer stageImplant placementCLINICAL QUESTION/LEVELPreferred reconstructive methodAdvanced breast tumorsTwo-stage implant reconstructionInvasive breast cancerBreast cancer screeningBreast cancer diagnosisUndergoing mastectomySubpectoral implantsDuctal carcinomaTherapeutic mastectomyCancer screeningTreatment recommendationsImplant reconstructionSubpectoral augmentationAuthors' institutionBreast augmentationMastectomyBreast tumors
2016
The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment
Obeng-Gyasi S, Tolnitch L, Greenup R, Shelley Hwang E. The Impact of the Affordable Care Act on North Carolinian Breast Cancer Patients Seeking Financial Support for Treatment. Annals Of Surgical Oncology 2016, 23: 3412-3417. PMID: 27411550, PMCID: PMC5994757, DOI: 10.1245/s10434-016-5311-3.Peer-Reviewed Original ResearchCan Vascular Patterns on Preoperative Magnetic Resonance Imaging Help Predict Skin Necrosis after Nipple-Sparing Mastectomy?
Bahl M, Pien I, Buretta K, Hwang E, Greenup R, Ghate S, Hollenbeck S. Can Vascular Patterns on Preoperative Magnetic Resonance Imaging Help Predict Skin Necrosis after Nipple-Sparing Mastectomy? Journal Of The American College Of Surgeons 2016, 223: 279-285. PMID: 27182036, DOI: 10.1016/j.jamcollsurg.2016.04.045.Peer-Reviewed Original ResearchConceptsNipple-sparing mastectomyNipple-areola complexSkin flap ischemiaBlood supplyFlap ischemiaSingle blood supplyPreoperative magnetic resonance imagingSurgical specimen weightPrevious radiation therapyPreoperative breast MRIDual blood supplyMajority of proceduresMagnetic resonance imagingNSM proceduresPatient demographicsSmoking historySurgical complicationsSurgical factorsSkin necrosisVascular findingsFemale patientsDecreased riskIncision typeSingle institutionMedical recordsSurgeons’ Perspectives of Contralateral Prophylactic Mastectomy
Bellavance E, Peppercorn J, Kronsberg S, Greenup R, Keune J, Lynch J, Collyar D, Magder L, Tilburt J, Hlubocky F, Yao K. Surgeons’ Perspectives of Contralateral Prophylactic Mastectomy. Annals Of Surgical Oncology 2016, 23: 2779-2787. PMID: 27169770, DOI: 10.1245/s10434-016-5253-9.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAttitude of Health PersonnelComprehensionFemaleGenes, BRCA1Genes, BRCA2HumansMaleMedical OveruseMiddle AgedPatientsPractice Patterns, Physicians'Prophylactic MastectomyRisk AssessmentRisk FactorsSurgical OncologySurveys and QuestionnairesUnilateral Breast NeoplasmsConceptsContralateral prophylactic mastectomyOncologic benefitProphylactic mastectomyBreast cancerBenefits of CPMUnfavorable risk/benefit ratioUse of CPMRisk/benefit ratioAverage-risk patientsDeleterious BRCA mutationsProportion of surgeonsInadequate patient understandingPercent of respondentsMedian ageBRCA mutationsBreast diseaseBreast surgeonsPractice patternsRelative riskPatient understandingCommon reasonMost surgeonsMethodsA surveyPatientsSurgeons
2015
Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ
Worni M, Akushevich I, Greenup R, Sarma D, Ryser M, Myers E, Hwang E. Trends in Treatment Patterns and Outcomes for Ductal Carcinoma in Situ. Journal Of The National Cancer Institute 2015, 107: djv263. PMID: 26424776, PMCID: PMC4707192, DOI: 10.1093/jnci/djv263.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedBiomarkers, TumorBreast NeoplasmsCarcinoma, Intraductal, NoninfiltratingConfounding Factors, EpidemiologicDisease-Free SurvivalFemaleHumansMastectomyMastectomy, Modified RadicalMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioProportional Hazards ModelsRadiotherapy, AdjuvantReceptors, EstrogenReceptors, ProgesteroneSEER ProgramSentinel Lymph Node BiopsySurvival AnalysisTreatment OutcomeUnited StatesConceptsOverall survivalTreatment patternsPre-invasive breast cancerSentinel lymph node biopsyCox proportional hazards regressionLocoregional treatment optionsNational treatment trendsEnd Results registryLymph node biopsyBreast cancer outcomesLong-term outcomesProportional hazards regressionPatient selection biasCochran-Armitage trend testInverse probability weightsDCIS patientsNode biopsyBilateral mastectomyDuctal carcinomaHazards regressionCancer outcomesTreatment optionsBreast cancerTreatment trendsLumpectomyEvaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI?
Bahl M, Baker J, Greenup R, Ghate S. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? Annals Of Surgical Oncology 2015, 22: 435-441. PMID: 26249144, DOI: 10.1245/s10434-015-4792-9.Peer-Reviewed Original ResearchConceptsPathologic nipple dischargeMagnetic resonance imagingNipple dischargeNegative predictive valuePositive predictive valuePredictive valueDiagnostic valueNegative magnetic resonance imagingSpecificity of MRIBreast magnetic resonance imagingEvaluation of patientsValuable additional diagnostic toolRadiology Breast Imaging ReportingBI-RADS 1Data System 4Detection of malignancyAdditional diagnostic toolBreast Imaging ReportingSonographic workupDuct explorationRetrospective reviewSurgical excisionRadiographic findingsDuctal carcinomaSymptomatic populationDiagnostic Value of Ultrasound in Female Patients With Nipple Discharge.
Bahl M, Baker J, Greenup R, Ghate S. Diagnostic Value of Ultrasound in Female Patients With Nipple Discharge. American Journal Of Roentgenology 2015, 205: 203-8. PMID: 26102400, DOI: 10.2214/ajr.14.13354.Peer-Reviewed Original ResearchConceptsPathologic nipple dischargeNipple dischargeInvasive adenocarcinomaSurgical excisionEvaluation of patientsDetection of DCISNormal sonographic findingsSpecificity of mammographySpecificity of ultrasoundUseful diagnostic toolContribution of ultrasoundBilateral mammographyFemale patientsPathologic featuresRadiologic findingsRetrospective reviewDuctal carcinomaSonographic findingsPathologic resultsStudy populationPatientsRoutine evaluationDiagnostic valueAdenocarcinomaUltrasound
2014
Management of Positive Sub‐areolar/Nipple Duct Margins in Nipple‐Sparing Mastectomies
Camp M, Coopey S, Tang R, Colwell A, Specht M, Greenup R, Gadd M, Brachtel E, Austen W, Smith B. Management of Positive Sub‐areolar/Nipple Duct Margins in Nipple‐Sparing Mastectomies. The Breast Journal 2014, 20: 402-407. PMID: 24890641, DOI: 10.1111/tbj.12279.Peer-Reviewed Original ResearchConceptsNipple-sparing mastectomyNipple-areola complexPositive marginsNAC specimensCancer-bearing breastsResidual invasive cancerRetrospective chart reviewInvasive lobular carcinomaResidual DCISChart reviewResidual malignancyDuctal carcinomaInvasive cancerLobular carcinomaProphylactic mastectomyDuctal tissueAreola complexTreatment informationMastectomyCarcinomaTissue removalNippleFuture studiesDCISMalignancy
2013
Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort
Greenup R, Buchanan A, Lorizio W, Rhoads K, Chan S, Leedom T, King R, McLennan J, Crawford B, Kelly Marcom P, Shelley Hwang E. Prevalence of BRCA Mutations Among Women with Triple-Negative Breast Cancer (TNBC) in a Genetic Counseling Cohort. Annals Of Surgical Oncology 2013, 20: 3254-3258. PMID: 23975317, DOI: 10.1245/s10434-013-3205-1.Peer-Reviewed Original ResearchConceptsTriple-negative breast cancerBRCA mutation prevalenceRace/ethnicityBRCA mutationsGenetic counselingBreast cancerMutation prevalenceGenetic mutationsAfrican AmericansHereditary cancer clinicBRCA mutation statusBRCA genetic mutationPersonalized genetic counselingConclusionsThe prevalenceNCCN guidelinesPrimary outcomeRetrospective reviewTNBC subtypesResultsA totalBRCA2 mutationsCancer clinicMutation statusDemographic dataPrevalenceEthnicity/race
2012
Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer
Greenup R, Camp M, Taghian A, Buckley J, Coopey S, Gadd M, Hughes K, Specht M, Smith B. Cost Comparison of Radiation Treatment Options After Lumpectomy for Breast Cancer. Annals Of Surgical Oncology 2012, 19: 3275-3281. PMID: 22851048, DOI: 10.1245/s10434-012-2546-5.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBrachytherapyBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, Intraductal, NoninfiltratingCarcinoma, LobularCombined Modality TherapyCosts and Cost AnalysisFemaleFollow-Up StudiesHealth Care CostsHumansMastectomy, SegmentalMiddle AgedNeoplasm GradingNeoplasm InvasivenessPrognosisRetrospective StudiesConceptsWhole breast radiation therapyBreast cancerRT optionsExternal-beam partial breast irradiationLeukemia Group B 9343MethodsAn institutional review boardResultsMedian patient ageCurrent Procedural Terminology codesMedian tumor sizeInvasive ductal cancerSitu breast cancerPartial breast irradiationProcedural Terminology codesRadiation treatment optionsInstitutional review boardC-RTBackgroundRadiation therapyRT regimensBreast conservationDuctal cancerLobular cancerMixed histologyPatient ageRetrospective reviewTumor histology